Prismís founder is Elizabeth Silverman, formerly a senior biotechnology research analyst with Robertson Stephens and Punk Ziegel. Ms. Silverman began her career on Wall Street as a junior analyst with Alex. Brown & Sons.She is the author of numerous company research reports as well as two widely read special technology assessments (Genomics: An Investorís Guide and Gene Therapy: An Investorís Guide). In addition she created a unique monthly research product, The Genomics Digest to keep investors up to date on that fast moving field. Ms. Silverman has also researched companies across a wide range of technological and therapeutic categories including computer assisted drug design, instrumentation, diagnostics, neuroscience, cardiovascular, metabolic, anti-infectives, immunology and inflammation, among others. She has participated in a variety of IPOs and private placements, assisting companies with positioning, investors presentations and valuation. In addition, Ms. Silverman has been a featured speaker worldwide at industry conferences and events.
Ms. Silverman holds an AB degree from the University of Chicago in biological sciences, an MA degree from Columbia University in Genetics and an MBA from New York University.